Kukje Pharma Co., Ltd. (002720.KS)
KRW 4970.0
(-2.17%)
KRW 4970.0
(-2.17%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 475.74 Million KRW | -60.23% |
| 2022 | 1.19 Billion KRW | -26.18% |
| 2021 | 1.62 Billion KRW | -57.27% |
| 2020 | 3.79 Billion KRW | 68.07% |
| 2019 | 2.25 Billion KRW | 0.0% |
| 2018 | - KRW | -100.0% |
| 2017 | 4 Billion KRW | 100.0% |
| 2016 | 2 Billion KRW | -92.59% |
| 2015 | 27 Billion KRW | 285.71% |
| 2014 | 7 Billion KRW | -71.13% |
| 2013 | 24.24 Billion KRW | 3133.59% |
| 2012 | 749.94 Million KRW | -97.66% |
| 2011 | 31.99 Billion KRW | 207.09% |
| 2010 | 10.41 Billion KRW | -67.86% |
| 2009 | 32.42 Billion KRW | 37.49% |
| 2008 | 23.58 Billion KRW | 220.13% |
| 2007 | 7.36 Billion KRW | 3583.7% |
| 2006 | 199.98 Million KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 455.16 Million KRW | 0.0% |
| 2024 Q1 | 410.95 Million KRW | 100.0% |
| 2023 Q3 | 791.46 Million KRW | -36.36% |
| 2023 Q4 | 475.74 Million KRW | -39.89% |
| 2023 Q1 | 1.32 Billion KRW | 10.89% |
| 2023 Q2 | 1.24 Billion KRW | -6.23% |
| 2023 FY | 475.74 Million KRW | -60.23% |
| 2022 Q1 | 1.79 Billion KRW | 10.61% |
| 2022 FY | 1.19 Billion KRW | -26.18% |
| 2022 Q4 | 1.19 Billion KRW | -23.18% |
| 2022 Q3 | 1.55 Billion KRW | -8.03% |
| 2022 Q2 | 1.69 Billion KRW | -5.54% |
| 2021 Q2 | 3.79 Billion KRW | -2.27% |
| 2021 Q1 | 3.88 Billion KRW | 2.41% |
| 2021 FY | 1.62 Billion KRW | -57.27% |
| 2021 Q4 | 1.62 Billion KRW | -5.11% |
| 2021 Q3 | 1.7 Billion KRW | -55.01% |
| 2020 Q1 | 5.57 Billion KRW | 147.2% |
| 2020 Q3 | 5.69 Billion KRW | 2.88% |
| 2020 Q4 | 3.79 Billion KRW | -33.46% |
| 2020 FY | 3.79 Billion KRW | 68.07% |
| 2020 Q2 | 5.53 Billion KRW | -0.69% |
| 2019 Q4 | 2.25 Billion KRW | -3.13% |
| 2019 FY | 2.25 Billion KRW | 0.0% |
| 2019 Q3 | 2.32 Billion KRW | 566.75% |
| 2019 Q2 | 349.33 Million KRW | -12.42% |
| 2019 Q1 | 398.88 Million KRW | 0.0% |
| 2018 Q4 | - KRW | 0.0% |
| 2018 FY | - KRW | -100.0% |
| 2018 Q1 | 2 Billion KRW | -50.0% |
| 2018 Q2 | 2 Billion KRW | 0.0% |
| 2018 Q3 | - KRW | -100.0% |
| 2017 Q1 | 4 Billion KRW | 100.0% |
| 2017 FY | 4 Billion KRW | 100.0% |
| 2017 Q4 | 4 Billion KRW | 0.0% |
| 2017 Q3 | 4 Billion KRW | 0.0% |
| 2017 Q2 | 4 Billion KRW | 0.0% |
| 2016 Q3 | 12 Billion KRW | -55.56% |
| 2016 Q2 | 27 Billion KRW | 0.0% |
| 2016 Q1 | 27 Billion KRW | 0.0% |
| 2016 FY | 2 Billion KRW | -92.59% |
| 2016 Q4 | 2 Billion KRW | -83.33% |
| 2015 Q3 | 20 Billion KRW | 185.71% |
| 2015 Q2 | 7 Billion KRW | 0.0% |
| 2015 Q1 | 7 Billion KRW | 0.0% |
| 2015 FY | 27 Billion KRW | 285.71% |
| 2015 Q4 | 27 Billion KRW | 35.0% |
| 2014 Q3 | 17 Billion KRW | -29.17% |
| 2014 Q1 | 24.12 Billion KRW | -0.52% |
| 2014 Q4 | 7 Billion KRW | -58.82% |
| 2014 FY | 7 Billion KRW | -71.13% |
| 2014 Q2 | 24 Billion KRW | -0.52% |
| 2013 FY | 24.24 Billion KRW | 3133.59% |
| 2013 Q2 | 499.96 Million KRW | -20.0% |
| 2013 Q3 | 9.37 Billion KRW | 1775.14% |
| 2013 Q4 | 24.24 Billion KRW | 158.67% |
| 2013 Q1 | 624.95 Million KRW | -16.67% |
| 2012 Q1 | 31.49 Billion KRW | 0.0% |
| 2012 Q4 | 749.94 Million KRW | 0.0% |
| 2012 FY | 749.94 Million KRW | -97.66% |
| 2011 FY | 31.99 Billion KRW | 207.09% |
| 2011 Q1 | 10.41 Billion KRW | 74.87% |
| 2011 Q2 | 9.89 Billion KRW | -5.01% |
| 2011 Q3 | 17.52 Billion KRW | 77.03% |
| 2010 Q4 | 5.95 Billion KRW | -70.89% |
| 2010 FY | 10.41 Billion KRW | -67.86% |
| 2010 Q2 | 29.13 Billion KRW | -10.13% |
| 2010 Q3 | 20.46 Billion KRW | -29.76% |
| 2010 Q1 | 32.42 Billion KRW | -1.85% |
| 2009 FY | 32.42 Billion KRW | 37.49% |
| 2009 Q4 | 33.03 Billion KRW | 14.65% |
| 2009 Q3 | 28.81 Billion KRW | -0.98% |
| 2009 Q2 | 29.09 Billion KRW | 23.39% |
| 2009 Q1 | 23.58 Billion KRW | 1.46% |
| 2008 Q1 | 7.36 Billion KRW | 11.62% |
| 2008 Q2 | 7.09 Billion KRW | -3.71% |
| 2008 Q4 | 23.24 Billion KRW | 95.38% |
| 2008 Q3 | 11.89 Billion KRW | 67.71% |
| 2008 FY | 23.58 Billion KRW | 220.13% |
| 2007 Q2 | 6.66 Billion KRW | 0.0% |
| 2007 Q4 | 6.59 Billion KRW | -0.5% |
| 2007 FY | 7.36 Billion KRW | 3583.7% |
| 2007 Q3 | 6.63 Billion KRW | -0.5% |
| 2006 FY | 199.98 Million KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 96.512% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 99.765% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 98.408% |
| HANDOK Inc. | 123.78 Billion KRW | 99.616% |
| Yuhan Corporation | 60.23 Billion KRW | 99.21% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 99.706% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -367.249% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 99.42% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | 19.408% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 92.136% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | 97.432% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | 96.22% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | 70.245% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 96.512% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -297.518% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 99.607% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 98.513% |
| JW Holdings Corporation | 20.65 Billion KRW | 97.697% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | 96.791% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 98.414% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 98.414% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -117.273% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | 18.067% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 99.04% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | 89.314% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 96.512% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 97.5% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 99.491% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 98.414% |
| Yuhan Corporation | 60.23 Billion KRW | 99.21% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | 95.469% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 98.822% |
| Suheung Co., Ltd. | 74 Billion KRW | 99.357% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 98.414% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | 88.582% |
| Korea United Pharm Inc. | 10.96 Billion KRW | 95.66% |
| CKD Bio Corp. | 69.43 Billion KRW | 99.315% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 98.624% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | 97.05% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -54.937% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -117.273% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 99.34% |
| Boryung Corporation | 151.7 Billion KRW | 99.686% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 99.394% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 92.136% |
| JW Lifescience Corporation | 168 Million KRW | -183.18% |